Biofidelity Raises $23M in Series A+ Financing
- Biofidelity, a Cambridge UK-based cancer diagnostic company, raised $23M in Series A+ funding
- The round was led by Octopus Ventures and backed by SBI Investment Co. Ltd., and existing investors
- The company intends to use the funds to expand its development efforts and launch ASPYRE-Lung, its first commercial diagnostic assay based on its molecular technology
- The company is a molecular diagnostics company unlocking the benefits of precision medicine for all patients by increasing access to early detection, precision diagnosis and routine monitoring
- ASPYRE is a completely new category of molecular diagnostic technology that simplifies and accelerates the detection of genomic biomarkers
- While the company’s initial focus is on non-small cell lung cancer (NSCLC), it intends to expand this to broad application across the $15 billion cancer testing market
